Monday, December 14, 2009 9:53:15 PM
for those who want more science on 13739 see this
http://www.incyte.com/pdfs/EASD_2009_INCB13739.pdf
http://www.incyte.com/pdfs/EASD_2009_INCB13739.pdf
Recent INCY News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:10:15 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:09:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/30/2026 09:35:18 PM
- Incyte annonce de nouvelles données positives de dernière minute portant sur 54 semaines concernant le povorcitinib dans le traitement de l’hidradénite suppurée lors du congrès annuel 2026 de l’Académie américaine de dermatologie (AAD) • Business Wire • 03/29/2026 05:51:00 PM
- Incyte präsentiert neue positive 54-Wochen-Daten zu Povorcitinib bei Hidradenitis suppurativa auf der Jahrestagung 2026 der American Academy of Dermatology (AAD) • Business Wire • 03/29/2026 05:10:00 PM
- Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting • Business Wire • 03/28/2026 07:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/26/2026 08:13:52 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/26/2026 12:38:39 PM
- Incyte annonce des nominations au sein de sa haute direction • Business Wire • 03/25/2026 08:17:00 PM
- Incyte verkündet Ernennung von Führungspersonal • Business Wire • 03/25/2026 07:57:00 PM
- Incyte Announces Executive Leadership Appointments • Business Wire • 03/25/2026 01:00:00 PM
- Incyte présentera des données de dernière minute sur l’hidradénite suppurée lors du congrès annuel 2026 de l’Académie américaine de dermatologie (AAD) • Business Wire • 03/20/2026 11:42:00 PM
- Incyte wird auf der Jahrestagung 2026 der American Academy of Dermatology (AAD) die neuesten Daten aus der Hidradenitis suppurativa-Forschung vorstellen • Business Wire • 03/20/2026 11:42:00 PM
- Incyte to Highlight Late-Breaking Hidradenitis Suppurativa Data at the 2026 American Academy of Dermatology (AAD) Annual Meeting • Business Wire • 03/20/2026 02:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/19/2026 08:20:22 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/17/2026 08:07:08 PM
- Knight Therapeutics Announces Regulatory Supplemental Submission of MINJUVI® (tafasitamab) for Follicular Lymphoma in Argentina and Mexico • GlobeNewswire Inc. • 03/17/2026 11:30:00 AM
- Knight Therapeutics Announces Approval of Additional Indication for MINJUVI® (tafasitamab) in Brazil • GlobeNewswire Inc. • 03/17/2026 11:30:00 AM
- Incyte meldet die Zulassung von Zynyz® (Retifanlimab) durch die Europäische Kommission für die Erstlinienbehandlung von fortgeschrittenem Plattenepithelkarzinom des Analkanals (Squamous Cell Carcinoma of the Anal Canal, SCAC) • Business Wire • 03/07/2026 04:00:00 PM
- Incyte annonce l’autorisation par la Commission européenne de Zynyz® (rétifanlimab) pour le traitement de première intention du carcinome épidermoïde avancé du canal anal (SCAC) • Business Wire • 03/07/2026 04:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2026 10:03:47 PM
- Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC) • Business Wire • 03/06/2026 09:42:00 PM
- Lilly's Olumiant (baricitinib) recommended by CHMP for approval of expanded use in the European Union for adolescents with severe alopecia areata • PR Newswire (US) • 02/27/2026 01:11:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/23/2026 09:05:14 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/19/2026 09:02:14 PM
